Sebia launches M-inSight, a test for monitoring multiple myeloma patients

Sept. 29, 2023
Multiple myeloma is the second most common blood cancer in the world, affecting more than 170,000 people worldwide.

Sebia announced the launch of its serum based Minimal Residual Disease (MRD) test for monitoring in multiple myeloma. M-inSight is a Laboratory Developed Test (LDT) being offered by Corgenix, College of American Pathologists (CAP)-accredited, Clinical Laboratory Improvement Amendments (CLIA) – licensed clinical laboratory and part of the Sebia Group. 

M-inSight is a personalized, targeted mass spectrometry assay, to detect with sensitivity the monoclonal protein (M-protein) secreted by the patient’s tumor cells in serum. The technology is based on clonotypic peptides mass spectrometry, which avoids the interference with the polyclonal background leading to an ultra-sensitive test. 

Read the full release here